Abnormal Properties and Behaviors of Antithrombin III Found in a Thrombophilic Patient: Defective Biological Functions and Dissimilar Antigenic Determinants

Hideki Murayama; Michio Matsuda

doi:10.1055/s-0038-1661633

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1986; 56(02): 165-171
DOI: 10.1055/s-0038-1661633

Original Article

Schattauer GmbH Stuttgart

Abnormal Properties and Behaviors of Antithrombin III Found in a Thrombophilic Patient: Defective Biological Functions and Dissimilar Antigenic Determinants

Hideki Murayama

The Department of Surgery and Division of Hemostasis and Thrombosis Research, Institute of Hematology Jichi Medical School, Tochigi-Ken, Japan

,

Michio Matsuda

The Department of Surgery and Division of Hemostasis and Thrombosis Research, Institute of Hematology Jichi Medical School, Tochigi-Ken, Japan

› Author Affiliations

Abstract

PDF Download

Summary

Abnormal properties of antithrombin III have been found in a 55-year-old male who has been thrombophilic over the last seven years. They are characterized by 1) defective inhibition of thrombin and activated blood coagulation factor X, 2) reduced affinity to heparin and 3) partial immunological identity with the normal molecule. The antithrombin III molecule, however, preserves a single-chain structure and an apparently identical molecular weight with that of the normal molecule. It is, thus, very unlikely that the impaired functions of antithrombin III in the patient’s plasma are induced by possible proteolytic modifications of the molecule by thrombin or other related activated blood coagulation factors.

Since no other members of his immediate family have been found to be affected, the abnormality may be acquired rather than genetically determined, although further investigation is necessary for the elucidation of the abnormality of the molecule.

Key words

Antithrombin III - Abnormal properties of antithrombin III - Thrombosis - Mesenteric vein thrombosis

PDF (261 kb)

References

References
1 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516-530
2 Sas G, Blasko G, Banghegyi D, Jako J, Palos LA. Abnormal antithrombin III (antithrombin “Budapest”) as a cause of a familial thrombophilia. Thromb Diath Haemorrh 1974; 32: 105-105
3 Von Kaulla E, von Kaulla KN. Deficiency of antithrombin III activity associated with hereditary thrombosis tendency. J Med 1972; 3: 349-358
4 Meer JVan der, Stoepman-Van DalenE A, Jensen JM S. Antithrombin III deficiency in a Dutch family. J Clin Pathol 1973; 26: 532-538
5 Marciniak E, Farley CH, DeSimone PA. Familial thrombosis due to antithrombin III deficiency. Blood 1974; 43: 219-231
6 Bjarke B, Herin P, Blomback M. Neonatal aortic thrombosis. A possible clinical manifestation of congenital antithrombin III deficiency. Acta Paediat Scand 1974; 63: 297-301
7 Gruenberg J, Smallridge RC, Rosenberg RD. Inherited antithrombin’ III deficiency causing mesenteric venous infarction: A new clinical entity. Ann Surg 1975; 181: 791-794
8 Mendelsohn G, Gomperts ED, Gurwitz D. Severe antithrombin III deficiency in an infant associated with multiple arterial and venous thrombosis. Thromb Haemostas 1976; 36: 495-502
9 Rubinowitz MJ, Ford C. Familial antithrombin III deficiency. An important clinical entity. Rocky Mountain Medical Journal 1977; 74: 246-249
10 Watel A, Goudemand J, Zandecki M, Laisne C, Bertrand ME, Cosson A. Déficit familial en antithrombin III et maladie thromboem-bolique. Little Medical 1978; 23: 555-560
11 Sakuragawa N, Takahashi K, Kondo S, Koide T. Antithrombin III Toyama: A hereditary abnormal antithrombin III (antithrombin III Toyama) of patient with recurrent thrombophlebitis. Thromb Res 1983; 31: 305-317
12 Bauer KA, Ashenhurst JB, Chediak J, Rosenberg RD. Antithrombin “Chicago”: A functionally abnormal molecule with increased heparin affinity causing familial thrombophilia. Blood 1983; 62: 1242-1250
13 Koide T, Odani S, Takahashi K, Ono T, Sakuragawa N. Antithrombin III Toyama: Replacement of arginine-47 by cysteins in hereditary abnormal antithrombin III that lacks heparin-binding ability. Proc Natl Acad Sci USA 1984; 81: 289-293
14 Chang J, Tran T. Antithrombin Basel. Identification of a Pro-Leu substitution in a hereditary abnormal antithrombin with impaired heparin cofactor activity. J Biol Chem 1986; 261: 1174-1176
15 Duke WW. The relation of blood platelets to hemorrhagic disease. Description of a method for determining the bleeding time and coagulation time and report of three cases with hemorrhagic disease relieved by transfusion. JAMA 1910; 55: 1185-1188
16 Born GV R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929
17 Tocantins LA, Kazal LA. (eds) Blood Coagulation, Hemorrhage and Thrombosis. Methods of Study. Grune & Stratton, Inc; New York: 1964
18 Ratnoff OD, Menzie C. A new method for the determination of fibrinogen in small samples of plasma. J Lab Clin Med 1951; 37: 316-320
19 Quick AJ, Stanley-Brown M, Bancroft FW. A study of the coagulation defect in hemophilia and in jaundice. Am J Med Sci 1935; 190: 501-511
20 Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin: a simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol 1961; 36: 212-219
21 Lorand L, Urayama I, Kiewit JW C, Nossel HL. Diagnostic and genetic studies of fibrin-stabilizing factor with a new assay based on amine incorporation. J Clin Invest 1969; 48: 1054-1063
22 Merskey C, Kleiner GJ, Jackson AJ. Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment. Blood 1966; 28: 01-18
23 Goodnight Jr SH, Shaeffer JL, Seth K. Measurement of antithrombin III in normal and pathologic states using chromogenic substrate S-2238. Comparison with immunoelectrophoretic and factor Xa inhibition assay. Am J Clin Pathol 1980; 73: 639-647
24 Ødegard OR, Lie M, Abildgaad U. Antifactor Xa activity measured with amidolytic methods. Haemostasis 1976; 5: 265-275
25 Yamagishi R, Niwa M, Kondo S, Sakuragawa N, Koide T. Purification and biological property of heparin cofactor II: activation of heparin cofactor II and antithrombin III by dextran sulfate and various glycosaminoglycans. Thromb Res 1984; 36: 633-642
26 Laemmli VK. Cleavage of structural proteins during assembly of head bacteriophage T4. Nature 1970; 227: 680-685
27 Salacinski PR P, McLean C, Sykes JE C, Clement-Jones VV, Lowry PJ. Iodination of proteins, glycoproteins, and peptides using a solid phase oxidizing agent, l,3,4,6-tetrachloro-3α, 6α-diphenyl glycoluril(iodogen). Anal Biochem 1981; 117: 136-146
28 Miller-Anderson M, Borg H, Anderson L-O. Purification of antithrombin III by affinity chromatography. Thromb Res 1974; 5: 439-452
29 Laurell CB. Quantitative estimation of proteins by electrophoresis in agarose gel containing antibodies. Anal Biochem 1966; 15: 45-52
30 Ganrot PO. Crossed immunoelectrophoresis. Scand J Clin Lab Invest 1972; 29 (Suppl.) (Suppl. 124) 39-47
31 McKay EJ. A simple two-step procedure for the isolation of antithrombin III from biological fluids. Thromb Res 1981; 21: 375-382
32 Denson KW E. The preparation of general reagents and coagulation factors. In Human Blood Coagulation, Haemostasis and Thrombosis Biggs R. (ed.) p 590 Oxford: Blackwell Scientific Publications; 1972
33 Weber K, Osborn M. The reliability of molecular weight determination by dodecyl sulfate-polyacrylamide gel electrophoresis. J Biol Chem 1969; 30: 1190-1206
34 Sommer T. Hyperviscosity syndrome in plasma cell dyscrasias. Advances in Microcirculation 1975; 6: 01-55
35 Suzuki K, Nishioka J, Hashimoto S. Protein C inhibitor: purification from human plasma and characterization. J Biol Chem 1983; 258: 163-168
36 Aoki N, Yamanaka T. The α₂-plasmin inhibitor levels in liver diseases. Clin Chim Acta 1978; 84: 099-105
37 Hallen J, Laurell CB. Plasma protein pattern in cirrhosis of the liver. Scand J Clin Lab Invest 1972; 29 (Supplem.) (Suppl. 124) 097-103
38 Tollefsen DM, Blank MK. Detection of a new heparin-dependent inhibitor of thrombin in human plasma. J Clin Invest 1981; 68: 589-596
39 Tollefsen DM, Majerus DW, Blank MK. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. J Biol Chem 1982; 257: 2162-2169
40 Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 1973; 248: 6490-6505
41 Fish WW, Orre K, Bjork I. Routes of thrombin action in the production of proteolytically modified, secondary forms of antithrombin-thrombin complex. Eur J Biochem 1979; 101: 39-44
42 Jesty J. Dissociation of complexes and their derivatives formed during inhibition of bovine thrombin and activated factor X by antithrombin III. J Biol Chem 1979; 254: 1044-1049
43 Fish WW, Bjork I. Release of a two-chain form of antithrombin from the antithrombin-thrombin complex. Eur J Biochem 1979; 101: 31-38
44 Griffith MJ, Lundblad RL. Dissociation of antithrombin III-thrombin complex. Formation of active and inactive antithrombin III. Biochemistry 1981; 20: 105-110
45 Bjork I, Jackson CM, Jornvall H, Lavine KK, Nordling K, Salsgiver WJ. The active site of antithrombin. Release of the same proteolytically cleaved form of the inhibitor from complexes with factor IXa, factor Xa and thrombin. J Biol Chem 1982; 257: 2406-2411
46 Tollefsen DM, Pestka CA, Monafo WJ. Activation of heparin cofactor II by dermatan sulfate. J Biol Chem 1983; 258: 6713-6716